通策医疗股份有限公司的主营业务是口腔医疗服务的提供、研发。公司的主要产品是医疗服务、产品销 售、建筑工程、综合服务费。 最新一期业绩显示，2025年一季报，公司实现营业收入7.45亿元，同比5.11%；净利润1.84亿元，同比 6.22%，销售毛利率44.21%。 8月4日，通策医疗今日收盘45.33元，下跌1.71%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到39.59倍，总市值202.76亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均47.79倍，行业中值59.03倍，通策医疗排 名第24位。 股东方面，截至2025年5月28日，通策医疗股东户数83145户，较上次减少1346户，户均持股市值35.28 万元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8通策医疗39.5940.444.82202.76亿行业平均 47.7959.864.17195.49亿行业中值59.0364.343.1867.01亿1药明康德19.1627.924.402638.13亿2康龙化成 28.3729.563.77530.08亿3爱尔眼科32.4133. ...

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Group 1 - The core point of the news is that Tongce Medical has experienced significant trading activity in the margin financing market, with a net sell-off observed recently [1] - On August 1, Tongce Medical had a financing buy-in amount of 0.82 billion yuan, ranking 205th in the two markets, while the financing repayment amount was 0.98 billion yuan, resulting in a net sell-off of 16.37 million yuan [1] - Over the last three trading days, from July 30 to August 1, Tongce Medical received financing buy-ins of 1.35 billion yuan, 1.18 billion yuan, and 0.82 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were 0.38 thousand shares sold short, with a net buy of 0.19 thousand shares [2]

融券方面，当日融券卖出0.17万股，净买入0.78万股。 来源：金融界 7月31日，沪深两融数据显示，通策医疗获融资买入额1.18亿元，居两市第174位，当日融资偿还额1.15 亿元，净买入240.43万元。 最近三个交易日，29日-31日，通策医疗分别获融资买入1.42亿元、1.35亿元、1.18亿元。 ...

Group 1 - Goldman Sachs highlights certain healthcare services and treatments, such as high-end dental implants, cataract surgeries, and specific vaccines, which are not covered by national health insurance or affected by centralized drug procurement, indicating strong potential for continued growth in out-of-pocket medical spending among the "silver-haired" population (aged 50 and above) [1] - Goldman Sachs has upgraded ratings for several stocks expected to benefit from the growth in high-end out-of-pocket treatment projects, including Eye Care (300015.SZ) and Zhifei Biological (300122.SZ) to "Buy," while also rating Purui Eye Care (301239.SZ) and Straumann (SAUHY.US) as "Buy," and upgrading Shengtong Medical (600763.SH) to "Neutral" [1] Group 2 - Goldman Sachs focuses on the "silver-haired" demographic, which possesses strong consumption capability with net assets exceeding 3 million RMB, estimating a total addressable market (TAM) that will grow from 221 billion RMB (31 billion USD) in 2024 to 963 billion RMB (135 billion USD) by 2035, with a compound annual growth rate (CAGR) of 14.3% [2] - The report indicates that in 2024, this demographic will account for only 3% of the total population aged 50 and above but will contribute 5% of the healthcare spending for this group, with expectations that this contribution will rise to 13% by 2035 [2] - Goldman Sachs projects the CAGR for healthcare spending among individuals aged 50 and above with net assets over 3 million RMB during 2024-2035 under baseline, optimistic, and pessimistic scenarios to be 14%, 19%, and 9% respectively [2]

融券方面，当日融券卖出0.91万股，净卖出0.81万股。 来源：金融界 7月30日，沪深两融数据显示，通策医疗获融资买入额1.35亿元，居两市第141位，当日融资偿还额1.46 亿元，净卖出1066.35万元。 最近三个交易日，28日-30日，通策医疗分别获融资买入1.05亿元、1.42亿元、1.35亿元。 ...

来源：金融界 最近三个交易日，25日-29日，通策医疗分别获融资买入1.65亿元、1.05亿元、1.42亿元。 融券方面，当日融券卖出0.29万股，净卖出0.07万股。 7月29日，沪深两融数据显示，通策医疗获融资买入额1.42亿元，居两市第136位，当日融资偿还额1.64 亿元，净卖出2148.29万元。 ...

Company Overview - Tongce Medical's closing price on July 29 was 46.64 yuan, with an increase of 1.50%, resulting in a rolling price-to-earnings (PE) ratio of 40.73 times and a total market capitalization of 20.862 billion yuan [1] - The company's main business is providing and researching oral medical services, with key products including medical services, product sales, construction engineering, and comprehensive service fees [1] Financial Performance - For the first quarter of 2025, Tongce Medical reported operating revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up 6.22% year-on-year, with a gross profit margin of 44.21% [1] Shareholder Information - As of May 28, 2025, Tongce Medical had 83,145 shareholders, a decrease of 1,346 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical services industry is 48.95 times, with a median of 60.06 times, placing Tongce Medical at the 23rd position within the industry [2] - The industry average market capitalization is 20.44 billion yuan, while the median is 66.76 billion yuan [2]

金融界7月29日消息，上证指数低开高走，上证养老产业指数 (上证养老，H50043)报7533.04点。 从指数持仓来看，上证养老产业指数十大权重分别为：博瑞医药（4.66%）、科沃斯（3.2%）、新华保 险（2.96%）、恒瑞医药（2.7%）、中国平安（2.64%）、中国太保（2.62%）、南京商旅（2.58%）、 通策医疗（2.55%）、中国中免（2.54%）、石头科技（2.54%）。 从上证养老产业指数持仓的市场板块来看，上海证券交易所占比100.00%。 从上证养老产业指数持仓样本的行业来看，可选消费占比36.84%、医药卫生占比36.08%、主要消费占 比11.40%、金融占比10.76%、通信服务占比4.92%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 数据统计显示，上证养老产业指数近一 ...

Core Insights - The rise of the "silver economy" indicates that the high-net-worth elderly population is expected to become a significant growth engine for the market [1][5]. Group 1: Market Dynamics - Goldman Sachs reports that the medical expenditures of individuals aged 50 and above with net assets exceeding 3 million yuan will be a key driver for the growth of the high-end medical market in China [2]. - This demographic, while only representing 3% of the population over 50, currently contributes 5% of total medical expenditures, which is projected to increase to 13% by 2035 as their population share grows to 5% [3][8]. - The medical spending of this group is expected to rise from 221 billion yuan in 2024 to 963 billion yuan by 2035, reflecting a compound annual growth rate (CAGR) of 14.3%, significantly higher than the overall elderly population growth rate of 5.3% and the all-age growth rate of 4.7% [3][7]. Group 2: Self-Payment Market - As national health insurance budgets tighten, the role of out-of-pocket (OOP) medical expenses is becoming increasingly important, with the self-payment ratio expected to rise from 65% in 2024 to 86% by 2035 [4][9]. - This shift indicates that traditional models reliant on insurance reimbursements are inadequate for meeting the needs of this affluent elderly demographic, which prefers high-quality, elective medical services [9]. Group 3: Health Trends and Opportunities - The report highlights a rising incidence of diseases such as tooth loss, cataracts, and diabetes among the over-50 population, suggesting a growing demand for early screening, preventive care, and high-quality treatment options [10]. - Companies that offer high-end and self-paid medical products are expected to benefit significantly, with revenue growth projected at 13%-21% CAGR, outpacing other business segments [11]. Group 4: Emerging Technologies - The report emphasizes the potential of cutting-edge technologies such as brain-machine interfaces, gene therapies, and rehabilitation robotics to reshape the healthcare industry [4][12]. - The global market for gene medicine is estimated to reach $4.8 trillion, driven by advancements in CRISPR/Cas9 technology and decreasing gene sequencing costs [12]. - Although these technologies are still in early stages, their early applications in healthcare present significant opportunities for growth in the high-end self-pay medical market [13].